

- **Name:** Keun-Wook Lee
- **Current Position & Affiliation:** Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital
- **Country:** Republic of Korea

• Educational Background:

| Institution and Location | Degree | Year | Field of study |
|---|--------|-----------|--------------------|
| Seoul National University College of Medicine | M.D. | 1992-1998 | General medicine |
| Seoul National University, Graduate School | M.S. | 2002~2004 | Internal medicine |
| Seoul National University, Graduate School | Ph.D. | 2004~2007 | Molecular oncology |

• Professional Experience:

- Medical Oncology (Focused on gastric, colorectal, and head and neck cancers)
- Cancer clinical trials including early phase clinical trials
- Translational research

• Professional Organizations:

| Institution and location | Position | Year-year |
|--|---------------------|-----------------|
| Seoul National University Hospital | Resident | 2000~2004 |
| Seoul National University Hospital | Clinical Fellowship | 2004~2005 |
| Division of Hematology-Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital | Clinical Professor | 2005~2013. |
| Division of Hematology-Oncology, Department of Internal Medicine, Seoul National University College of Medicine / Seoul National University Bundang Hospital | Associate Professor | 2013.9.~2018.2. |
| Division of Hematology-Oncology, Department of Internal Medicine, Seoul National University College of Medicine / Seoul National University Bundang Hospital | Professor | 2018.3.~Present |
| Division of Hematology-Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital | Chief | 2016.7.~2020.6. |
| Clinical Trial Center, Seoul National University Bundang Hospital | Chief | 2020.4.~Present |

• Main Scientific Publications:

| | | | | |
|---|--|--------|------------------|---|
| 1 | Enzastaurin, a protein kinase C β inhibitor, suppresses signaling through the ribosomal S6 kinase and Bad pathways and induces apoptosis in human gastric cancer cells | 200803 | Cancer Res | Lee KW, Kim SG, Kim HP, Kwon E, You J, Choi H, Park JH, Kang BC, Im SA, Kim TY, Kim WH, Bang YJ |
| 2 | The incidence, risk factors and prognostic implications of venous thromboembolism in patients with gastric cancer. | 201003 | J Thromb Haemost | Lee KW, Bang SM, Kim S, Lee HJ, Shin DY, Koh Y, Lee YG, Cha Y, Kim YJ, Kim JH, Park DJ, Kim HH, Oh D, Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh T S, Button P, Sirzén F, Noh SH; for the |
| 3 | Adjuvant capecitabine and oxalipatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial | 201201 | Lancet | Chang HJ, Lee KW, Kim JH, Bang SM, Kim YJ, Kim DW, Kang SB, Lee JS |
| 4 | Adjuvant capecitabine chemotherapy using a tailored-dose strategy in elderly patients with colon cancer | 201204 | Ann Oncol | |

15th Annual Meeting of the Korean Society of Medical Oncology & 2022 International Conference

| | | | | |
|----|---|--------|-------------------|--|
| 5 | Lacrimal drainage obstruction in gastric cancer patients receiving S-1 chemotherapy | 201208 | Ann Oncol | NJ Kim, C Park, DJ Park, HH. Kim, S Kim, YJ. Kim, JH Kim, JS Lee, YJ Bang, SI. Khwarg, H Choung, M J. Lee & KW Lee |
| 6 | A Prospective Study on the Incidence of Postoperative Venous Thromboembolism in Korean Gastric Cancer Patients: An Inquiry into the Application of Western Guidelines to Asian Cancer Patients | 201304 | PLoS One | Kim JW, Chun EJ, Choi SI, Park DJ, Kim HH, Bang SM, Kim MJ, Lee JH, Lee MS, Lee JO, Kim YJ, Kim JH, Lee JS, Lee KW |
| 7 | Gastric cancer with initial bone metastasis: A distinct group of diseases with poor prognosis | 201411 | Eur J Cancer | Kim YJ, Kim SH, Kim JW, Lee JO, Kim JH, Bang SM, Lee JS, Lee KW |
| 8 | Significant Association of oncogene YAP1 with Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients. | 201501 | Clin Cancer Res | Lee KW, Lee SS, Kim SB, Sohn BH, Lee HS, Jnag HJ, Park YY, Kopetz S, Kim SS, Oh SC, Lee JS |
| 9 | Phase I/II Study of Weekly Oraxol for the Second-Line Treatment of Patients With Metastatic or Recurrent Gastric Cancer | 201508 | Oncologist | Lee KW, Lee KH, Zang DY, Park YI, Shin DB, Kim JW, Im SA, Koh SA, Yu KS, Cho JY, Jung JA, Bang YJ |
| 10 | A Randomized, Multicenter, Phase II Study of Cetuximab With Docetaxel and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Cancer | 201510 | Oncologist | Lee KW, Koh Y, Kim SB, Shin SW, Kang JH, Wu HG, Sung MW, Keam B, Kim DW, Kim TM, Kim KH, Kwon TK, Hah JH, Kim IA, Ahn SH, Yoon DH, etc. |
| 11 | Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. | 201601 | Gastric Cancer | Kim JW, Nam KH, Ahn SH, Park DJ, Kim HH, Kim SH, Chang H, Lee JO, Kim YJ, Lee HS, Kim JH, Bang SM, Lee JS, Lee KW. |
| 12 | Prospective Study on the Incidence of Postoperative Venous Thromboembolism in Korean Patients with Colorectal Cancer. | 201607 | Cancer Res Treat | Lee E, Kang SB, Choi SI, Chun EJ, Kim MJ, Kim DW, Oh HK, Ihn MH, Kim JW, Bang SM, Lee JO, Kim YJ, Kim JH, Kim JS, Lee KW. |
| 13 | Development and Validation of a Six-Gene Recurrence Risk Score Assay for Gastric Cancer. | 201612 | Clin Cancer Res | Lee KW, Lee SS, Hwang JE, Jang HJ, Lee HS, Oh SC, Lee SH, Sohn BH, Kim SB, Shim JJ, Jeong W, Cha M, Choeng JH, Cho JY, Lim JY, etc. |
| 14 | Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial | 201712 | Lancet | Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT |
| 15 | Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. | 201712 | Lancet Oncol | Bang YJ, Xu RH, Chin K, Lee KW, Park SH, Rha SY, Shen L, Qin S, Xu N, Im SA, Locker G, Rowe P, Shi X, Hodgson D, Liu YZ, Boku N |
| 16 | S-1-Induced Lacrimal Drainage Obstruction and its Association with Ingredients/Metabolites of S-1 in Tears and Plasma: A Prospective Multi-Institutional Study | 201801 | Cancer Res Treat | Kim N, Kim JW, Baek JH, Kim JS, Choung HK, Kim TY, Lee KH, Bang YJ, Khwarg SI, Ahn SH, Park DJ, Kim HH, Chung JY, Ahn S, Lee KW |
| 17 | Phase I Pharmacokinetic Study of Nivolumab in Korean Patients with Advanced Solid Tumors | 201802 | Oncologist | Lee KW, Lee DH, Kang JH, Park JO, Kim SH, Hong YS, Kim ST, Oh DY, Bang YJ |
| 19 | A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First-line Therapy (KCSG ST 10-01). | 201901 | Oncologist | Lee KW, Maeng CH, Kim TY, Zang DY, Kim YH, Hwang IG, Oh SC, Chung JS, Song HS, Kim JW, Jeong SJ, Cho JY |
| 20 | Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer. | 201901 | Cancer Res Treat. | Kim JW, Kim JG, Kang BW, Chung IJ, Hong YS, Kim TY, Song HS, Lee KH, Zang DY, Ko YH, Song EK, Baek JH, Koo DH, Oh SY, Cho H, Lee KW. |
| 21 | Development and Validation of an Easy-to-Implement, Practical Algorithm for the Identification of Molecular Subtypes of Gastric Cancer: Prognostic and Therapeutic Implications. | 201912 | Oncologist | Koh J, Lee KW, Nam SK, Seo AN, Kim JW, Kim JW, Park DJ, Kim HH, Kim WH, Lee HS |
| 22 | PI3K-targeting strategy using alpelisib to enhance the antitumor effect of paclitaxel in human gastric cancer. | 202007 | Sci Rep | Kim KJ, Kim JW, Sung JH, Suh KJ, Lee JY, Kim SH, Lee JO, Kim JW, Kim YJ, Kim JH, Bang SM, Lee JS, Kim HK, Lee KW. |
| 23 | Phase I Escalation and Expansion Study of Bemarituzumab (FPA 144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma. | 202007 | J Clin Oncol | Catenacci DVT, Rasco D, Lee J, Rha SY, Lee KW, Bang YJ, Bendell J, Enzinger P, Marina N, Xiang H, Deng W, Powers J, Wainberg ZA |
| 24 | S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial | 202008 | Lancet Oncol | Kang YK, Chin K, Chung HC, Kadowaki S, Oh SC, Nakayama N, Lee KW, Hara H, Chung IJ, Tsuda M, Park SH, Hosaka H, Hironaka S, Miyata Y, Ryu MH, Baba H, Hyodo I, Bang YJ, Boku N. |
| 25 | Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | 202008 | Lancet Oncol | Catenacci DVT, Kang YK, Park H, Uronis HE, Lee KW, Ng MCH, Enzinger PC, Park SH, Gold PJ, Lacy J, Hochster HS, et al. |
| 26 | Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial) | 202101 | Gastric Cancer | Lee KW, Chung IJ, Ryu MH, Park YI, Nam BH, Oh HS, Lee KH, Han HS, Seo BG, Jo JC, Lee HR, Kim JW, Park SR, Cho SH, Kang YK; SOPP study investigators. |